This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akiyama, T. Articles by Akinaga, S. Search for Related Content PubMed PubMed Citation Articles by Akiyama, T. Articles by Akinaga, S.

G₁ Phase Accumulation Induced by UCN-01 Is Associated with Dephosphorylation of Rb and CDK2 Proteins as well as Induction of CDK Inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated Human Epidermoid Carcinoma A431 Cells

Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shimotogari 1188, Nagaizumi-cho, Sunto-gun, Shizuoka-ken 411 [T. A., M. S., M. O., S. A.], and Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Asahimachi 3-6-6, Machida-shi, Tokyo 194 [T. Y., T. T., T. M.], Japan

UCN-01 (7-hydroxyl-staurosporine) was originally isolated as a Ca²⁺- and phospholipid-dependent protein kinase C selective inhibitor and now is being developed as an anticancer agent. Results from our and other laboratories have suggested that UCN-01 induces preferential G₁-phase accumulation in several human tumor cell lines tested. To elucidate this mechanism, we examined the effects of UCN-01 on several cell cycle-regulatory proteins critical for G₁-S-phase transition in p53-mutated human epidermoid carcinoma A431 cells. After 24 h exposure at around 50% growth-inhibitory concentrations (IC₅₀s), 260 and 520 nM, UCN-01 induced the accumulation of pRb (the dephosphorylated retinoblastoma protein form). The protein expression of cyclin A but not cyclin E was markedly reduced and that of cyclin D1 was partially reduced under the same condition. UCN-01 also showed the concentration-dependent inhibitions of the activity of cyclin-dependent kinase 2 (CDK2) using histone H1 and pRb as substrates in vitro (IC₅₀, 530 and 640 nM, respectively). In addition, CDK2 activities of the cells pretreated with UCN-01 for 24 h at 260 and 520 nM were markedly inhibited, giving IC₅₀s of far less than 260 nM. When the same cell lysates were analyzed by Western blotting for CDK2, the lower band (e.g., active and phosphorylated CDK2) was remarkably reduced, in accordance with the reduced activity. Furthermore, UCN-01 induced the expression of the CDK inhibitor p21 protein and its complex formation with CDK2 after 24 h exposure at 260 and 520 nM, whereas the expression level was very low or undetectable in untreated or DNA-damaged cells. The increase of p21 mRNA levels was also induced under the same condition. UCN-01 further increased luciferase activities in A431 cells transiently transfected with p21 promoter-luciferase reporter plasmid after 24 h exposure at 260 and 520 nM. UCN-01 also increased the expression of the CDK inhibitor p27 protein after 24 h exposure at 260 and 520 nM. These results suggest that G₁-phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitors p21 and p27.

¹ To whom requests for reprints should be addressed.

Received 8/19/96. Accepted 2/20/97.

This article has been cited by other articles:

				B. Ewald, D. Sampath, and W. Plunkett H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation Mol. Cancer Ther., April 1, 2007; 6(4): 1239 - 1248. [Abstract] [Full Text] [PDF]

				G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]

				P. N. Lara Jr, P. C. Mack, T. Synold, P. Frankel, J. Longmate, P. H. Gumerlock, J. H. Doroshow, and D. R. Gandara The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial Clin. Cancer Res., June 15, 2005; 11(12): 4444 - 4450. [Abstract] [Full Text] [PDF]

				B. C. Dash and W. S. El-Deiry Phosphorylation of p21 in G2/M Promotes Cyclin B-Cdc2 Kinase Activity Mol. Cell. Biol., April 15, 2005; 25(8): 3364 - 3387. [Abstract] [Full Text] [PDF]

				E. Fuse, T. Kuwabara, A. Sparreboom, E. A. Sausville, and W. D. Figg Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology J. Clin. Pharmacol., April 1, 2005; 45(4): 394 - 403. [Abstract] [Full Text] [PDF]

				E. A. Sausville Indifferently Pursued or Unowned Drugs: Who Should Lead Where Companies Do Not Tread? J. Clin. Oncol., March 20, 2005; 23(9): 1796 - 1798. [Full Text] [PDF]

				J. Kortmansky, M. A. Shah, A. Kaubisch, A. Weyerbacher, S. Yi, W. Tong, R. Sowers, M. Gonen, E. O'Reilly, N. Kemeny, et al. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors J. Clin. Oncol., March 20, 2005; 23(9): 1875 - 1884. [Abstract] [Full Text] [PDF]

				E. C. Dees, S. D. Baker, S. O'Reilly, M. A. Rudek, S. B. Davidson, C. Aylesworth, K. Elza-Brown, M. A. Carducci, and R. C. Donehower A Phase I and Pharmacokinetic Study of Short Infusions of UCN-01 in Patients with Refractory Solid Tumors Clin. Cancer Res., January 15, 2005; 11(2): 664 - 671. [Abstract] [Full Text] [PDF]

				M. Katsuki, V. T. G. Chuang, K. Nishi, K. Kawahara, H. Nakayama, N. Yamaotsu, S. Hirono, and M. Otagiri Use of Photoaffinity Labeling and Site-directed Mutagenesis for Identification of the Key Residue Responsible for Extraordinarily High Affinity Binding of UCN-01 in Human {alpha}1-Acid Glycoprotein J. Biol. Chem., January 14, 2005; 280(2): 1384 - 1391. [Abstract] [Full Text] [PDF]

				M. L. Fishel, D. R. Newell, R. J. Griffin, R. Davison, L.-Z. Wang, N. J. Curtin, E. G. Zuhowski, K. Kasza, M. J. Egorin, R. C. Moschel, et al. Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 206 - 213. [Abstract] [Full Text] [PDF]

				S. Grant and P. Dent Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name? Mol. Cancer Ther., July 1, 2004; 3(7): 873 - 875. [Full Text] [PDF]

				M. M. Facchinetti, A. De Siervi, D. Toskos, and A. M. Senderowicz UCN-01-Induced Cell Cycle Arrest Requires the Transcriptional Induction of p21waf1/cip1 by Activation of Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Cancer Res., May 15, 2004; 64(10): 3629 - 3637. [Abstract] [Full Text] [PDF]

				M. Huigsloot, R. B. Tijdens, and B. van de Water Inhibition of Protein Kinase C{alpha} Enhances Anticancer Agent-Induced Loss of Anchorage-Independent Growth Regardless of Protection against Apoptosis by Bcl-2 Mol. Pharmacol., October 1, 2003; 64(4): 965 - 973. [Abstract] [Full Text] [PDF]

				V. Patel, T. Lahusen, C. Leethanakul, T. Igishi, M. Kremer, L. Quintanilla-Martinez, J. F. Ensley, E. A. Sausville, J. S. Gutkind, and A. M. Senderowicz Antitumor Activity of UCN-01 in Carcinomas of the Head and Neck Is Associated with Altered Expression of Cyclin D3 and p27KIP1 Clin. Cancer Res., November 1, 2002; 8(11): 3549 - 3560. [Abstract] [Full Text] [PDF]

				A. M. Senderowicz The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01 Oncologist, August 1, 2002; 7(90003): 12 - 19. [Abstract] [Full Text] [PDF]

				T. Yamauchi, M. J. Keating, and W. Plunkett UCN-01 (7-Hydroxystaurosporine) Inhibits DNA Repair and Increases Cytotoxicity in Normal Lymphocytes and Chronic Lymphocytic Leukemia Lymphocytes Mol. Cancer Ther., February 1, 2002; 1(4): 287 - 294. [Abstract] [Full Text] [PDF]

				Y. A. Elsayed and E. A. Sausville Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins Oncologist, December 1, 2001; 6(6): 517 - 537. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				M. V. Blagosklonny and A. B. Pardee Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells Cancer Res., June 1, 2001; 61(11): 4301 - 4305. [Abstract] [Full Text] [PDF]

				E. A. Sausville, S. G. Arbuck, R. Messmann, D. Headlee, K. S. Bauer, R. M. Lush, A. Murgo, W. D. Figg, T. Lahusen, S. Jaken, et al. Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms J. Clin. Oncol., April 15, 2001; 19(8): 2319 - 2333. [Abstract] [Full Text] [PDF]

				C.-T. Hsueh, Y.-C. Wu, and G. K. Schwartz UCN-01 Suppresses E2F-1 Mediated by Ubiquitin-proteasome-dependent Degradation Clin. Cancer Res., March 1, 2001; 7(3): 669 - 674. [Abstract] [Full Text]

				M. Omura-Minamisawa, M. B. Diccianni, A. Batova, R. C. Chang, L. J. Bridgeman, J. Yu, Esther de Wit, F. H. Kung, J. D. Pullen, and A. L. Yu In Vitro Sensitivity of T-Cell Lymphoblastic Leukemia to UCN-01 (7-Hydroxystaurosporine) Is Dependent on p16 Protein Status: A Pediatric Oncology Group Study Cancer Res., December 1, 2000; 60(23): 6573 - 6576. [Abstract] [Full Text]

				Y. Shiotsu, K. Yamashita, F. Kanai, Y. Ikuina, C. Murakata, M. Teramura, H. Mizoguchi, T. Tamaoki, and S. Akinaga Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia Blood, June 15, 2000; 95(12): 3771 - 3780. [Abstract] [Full Text] [PDF]

				E. A. SAUSVILLE, J. JOHNSON, M. ALLEY, D. ZAHAREVITZ, and A. M. SENDEROWICZ Inhibition of CDKs as a Therapeutic Modality Ann. N.Y. Acad. Sci., June 1, 2000; 910(1): 207 - 222. [Abstract] [Full Text] [PDF]

				A. M. Senderowicz and E. A. Sausville Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators J Natl Cancer Inst, March 1, 2000; 92(5): 376 - 387. [Abstract] [Full Text] [PDF]

				E. R. Sauter, M. Herlyn, S.-C. Liu, S. Litwin, and J. A. Ridge Prolonged Response to Antisense Cyclin D1 in a Human Squamous Cancer Xenograft Model Clin. Cancer Res., February 1, 2000; 6(2): 654 - 660. [Abstract] [Full Text]

				E. R. Sauter, M. Nesbit, S. Litwin, A. J. P. Klein-Szanto, S. Cheffetz, and M. Herlyn Antisense Cyclin D1 Induces Apoptosis and Tumor Shrinkage in Human Squamous Carcinomas Cancer Res., October 1, 1999; 59(19): 4876 - 4881. [Abstract] [Full Text] [PDF]

				K. Sugiyama, T. Akiyama, M. Shimizu, T. Tamaoki, C. Courage, A. Gescher, and S. Akinaga Decrease in Susceptibility Toward Induction of Apoptosis and Alteration in G1 Checkpoint Function as Determinants of Resistance of Human Lung Cancer Cells against the Antisignaling Drug UCN-01 (7-Hydroxystaurosporine) Cancer Res., September 1, 1999; 59(17): 4406 - 4412. [Abstract] [Full Text] [PDF]

				H. Jiang and L.-Y. Yang Cell Cycle Checkpoint Abrogator UCN-01 Inhibits DNA Repair: Association with Attenuation of the Interaction of XPA and ERCC1 Nucleotide Excision Repair Proteins Cancer Res., September 1, 1999; 59(18): 4529 - 4534. [Abstract] [Full Text] [PDF]

				P. C. Mack, D. R. Gandara, C. Bowen, M. J. Edelman, T. Paglieroni, J. B. Schnier, E. P. Gelmann, and P. H. Gumerlock RB Status as a Determinant of Response to UCN-01 in Non-Small Cell Lung Carcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2596 - 2604. [Abstract] [Full Text] [PDF]

				P. Pages, N. Benali, N. Saint-Laurent, J.-P. Esteve, A. V. Schally, J. Tkaczuk, N. Vaysse, C. Susini, and L. Buscail sst2 Somatostatin Receptor Mediates Cell Cycle Arrest and Induction of p27Kip1. EVIDENCE FOR THE ROLE OF SHP-1 J. Biol. Chem., May 21, 1999; 274(21): 15186 - 15193. [Abstract] [Full Text] [PDF]

				E. Fuse, H. Tanii, K. Takai, K. Asanome, N. Kurata, H. Kobayashi, T. Kuwabara, S. Kobayashi, and Y. Sugiyama Altered Pharmacokinetics of a Novel Anticancer Drug, UCN-01, Caused by Specific High Affinity Binding to {{alpha}}1-Acid Glycoprotein in Humans Cancer Res., March 1, 1999; 59(5): 1054 - 1060. [Abstract] [Full Text] [PDF]

				S. T. Harkin, G. M. Cohen, and A. Gescher Modulation of Apoptosis in Rat Thymocytes by Analogs of Staurosporine: Lack of Direct Association with Inhibition of Protein Kinase C Mol. Pharmacol., October 1, 1998; 54(4): 663 - 670. [Abstract] [Full Text]

				S. Leclerc, M. Garnier, R. Hoessel, D. Marko, J. A. Bibb, G. L. Snyder, P. Greengard, J. Biernat, Y.-Z. Wu, E.-M. Mandelkow, et al. Indirubins Inhibit Glycogen Synthase Kinase-3beta and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease. A PROPERTY COMMON TO MOST CYCLIN-DEPENDENT KINASE INHIBITORS? J. Biol. Chem., January 5, 2001; 276(1): 251 - 260. [Abstract] [Full Text] [PDF]